Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IONS

Ionis Pharmaceuticals Inc

Mar 06 • 04:00PM ET

74.04

-1.12 -1.49 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD NBIX ALNY PRTA ARWR SRPT FOLD

| Held by: VTI VB VBK VXF XBI IBB CGGR IWP SCHA IWF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.47	Insider Own	2.08%	Shs Outstand	163.30M	Perf Week	-8.76%
Market Cap	12.23B	Forward P/E	-	EPS next Y	-1.56	Insider Trans	-26.85%	Shs Float	161.76M	Perf Month	-12.88%
Enterprise Value	12.17B	PEG	-	EPS next Q	-0.83	Inst Own	102.80%	Short Float	9.57%	Perf Quarter	-9.53%
Income	-380.99M	P/S	12.96	EPS this Y	-58.34%	Inst Trans	-	Short Ratio	7.23	Perf Half Y	24.75%
Sales	943.38M	P/B	24.72	EPS next Y	58.63%	ROA	-11.67%	Short Interest	15.49M	Perf YTD	-6.41%
Book/sh	2.99	P/C	4.57	EPS next 5Y	-	ROE	-70.72%	52W High	86.74 -14.64%	Perf Year	115.30%
Cash/sh	16.21	P/FCF	-	EPS past 3/5Y	-7.82% 5.62%	ROIC	-14.38%	52W Low	23.95 209.14%	Perf 3Y	104.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	17.12% 5.29%	Gross Margin	96.72%	Volatility	4.07% 3.46%	Perf 5Y	40.28%
Dividend TTM	-	EV/Sales	12.90	EPS Y/Y TTM	22.08%	Oper. Margin	-40.52%	ATR (14)	2.87	Perf 10Y	85.98%
Dividend Ex-Date	-	Quick Ratio	3.81	Sales Y/Y TTM	33.71%	Profit Margin	-40.39%	RSI (14)	32.68	Recom	1.61
Dividend Gr. 3/5Y	- -	Current Ratio	3.83	EPS Q/Q	-114.77%	SMA20	-9.39%	Beta	0.38	Target Price	95.89
Payout	-	Debt/Eq	5.35	Sales Q/Q	-10.57%	SMA50	-8.78%	Rel Volume	0.87	Prev Close	75.16
Employees	1402	LT Debt/Eq	4.42	Earnings	Feb 25 BMO	SMA200	18.20%	Avg Volume	2.14M	Price	74.04
IPO	May 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.86% 28.74%	Trades		Volume	1,856,866	Change	-1.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$95
Oct-08-25	Upgrade	JP Morgan	Neutral → Overweight	$80
Sep-26-25	Upgrade	Goldman	Sell → Neutral	$65
Sep-03-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$70
Jul-31-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$62
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight	$57
Apr-07-25	Initiated	H.C. Wainwright	Buy	$45
Mar-31-25	Initiated	Redburn Atlantic	Neutral	$39
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31

Show Previous Ratings

Feb-28-26 07:36AM	Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance (MarketBeat)
Feb-27-26 07:00AM	Ionis to present new data supporting DAWNZERA (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting (Business Wire)
Feb-26-26 11:53PM	Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 (Insider Monkey)
10:04PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
07:00AM	Loading…
07:00AM	Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) (Business Wire)
Feb-25-26 04:32PM	Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) -5.29%
04:04PM	Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:21PM	Ionis Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:48PM	Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug (Benzinga)
12:30PM	Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:12AM	Ionis Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs (Business Wire)
Feb-20-26 09:15AM	Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS (Zacks)
07:05AM	Loading…
Feb-19-26 07:05AM	Ionis to present at upcoming investor conferences (Business Wire)
Feb-18-26 10:00AM	Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-17-26 02:58PM	Ionis updates time for fourth quarter and full year 2025 financial results webcast (Business Wire)
12:09PM	RNA-targeting small molecules: a new frontier of drug discovery (Pharmaceutical Technology)
Feb-11-26 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
07:05AM	Ionis to hold fourth quarter and full year 2025 financial results webcast (Business Wire)
Feb-04-26 08:31AM	GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook (Zacks)
Feb-03-26 04:40PM	The pioneering physician behind groundbreaking ASO therapy (CNBC TV)
12:00PM	Tweedy Browne's Strategic Moves: Significant Increase in CNH Industrial NV (GuruFocus.com)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
07:00AM	DAWNZERA (donidalorsen) approved in the European Union for hereditary angioedema (HAE) (Business Wire)
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
12:02PM	National Bank of Canada Sees Significant Reduction in Tweedy Browne International Value's Portfolio (GuruFocus.com)
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
07:00AM	Loading…
07:00AM	Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts (Business Wire)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks)
10:31AM	Cathie Wood Dumps $12.7 Million Worth of Meta Stock Amid Ray-Ban Smart Glasses Delay, Ark Loads Up On This Gaming Platform (Benzinga)
Jan-07-26 06:23AM	GSK, Ionis claim study success for RNA-based hepatitis B drug (BioPharma Dive)
02:15AM	Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B (Business Wire)
Jan-06-26 07:05AM	Ionis to present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 08:25AM	Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks)
Dec-04-25 01:09PM	Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals (Zacks)
11:30AM	Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-02-25 07:00AM	Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) (Business Wire)
Dec-01-25 07:00AM	Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG) (Business Wire)
Nov-20-25 10:01AM	Tweedy Browne's Strategic Moves: Alphabet Inc. Sees a -1.43% Portfolio Impact (GuruFocus.com)
Nov-14-25 07:00AM	DAWNZERA (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) (Business Wire)
Nov-13-25 12:39AM	Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes (Business Wire)
Nov-12-25 04:00PM	Ionis to present at upcoming investor conferences (Business Wire)
05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-11-25 04:05PM	Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes (Business Wire)
Nov-10-25 04:20PM	Merck's Heart Pill Slashes Cholesterol Levels in Test Patients (Barrons.com) -5.45%
Nov-08-25 09:40AM	Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions (Business Wire)
Nov-06-25 08:00AM	Ionis presents new data demonstrating long-term disease control with DAWNZERA (donidalorsen) at ACAAI 2025 Annual Meeting (Business Wire)
Oct-31-25 05:00PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
01:14PM	Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook (Zacks)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 09:30AM	Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics (Zacks)
08:15AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:14AM	Ionis Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports third quarter 2025 financial results and highlights progress on key programs (Business Wire)
Oct-27-25 07:00AM	Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions (Business Wire)
Oct-23-25 02:10PM	Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture (Business Wire)
Oct-22-25 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-21-25 08:00AM	Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (Business Wire)
Oct-16-25 07:05AM	Ionis to hold third quarter 2025 financial results webcast (Business Wire)
Oct-08-25 04:14PM	Why Ionis Stock Hit A Six-Year High And Snagged A Price-Target Hike (Investor's Business Daily)
09:45AM	Intel, FedEx downgraded: Wall Street's top analyst calls (The Fly)
09:35AM	Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike (Investor's Business Daily)
Oct-07-25 09:26AM	Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on (CNBC TV)
07:00AM	Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day (Business Wire)
Oct-02-25 01:35AM	Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results (Insider Monkey)
Sep-30-25 07:08PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-24-25 12:41PM	BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL (Zacks)
Sep-23-25 02:15PM	IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal (Zacks)
01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 07:00AM	Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease (Business Wire)
06:01AM	Ionis and Sobis Tryngolza gains approval in EU for FCS treatment (Pharmaceutical Technology)
Sep-19-25 07:00AM	TRYNGOLZA (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) (Business Wire)
Sep-18-25 07:07AM	Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs (BioPharma Dive)
Sep-12-25 07:00AM	Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases (Business Wire)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 07:00AM	Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome (Business Wire) +5.57%
Sep-08-25 04:00PM	Ionis to host investors and analysts for Innovation Day 2025 (Business Wire)
Sep-04-25 12:34PM	Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen (Insider Monkey)
Sep-03-25 11:13AM	Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results (Insider Monkey) +5.22%
10:47AM	IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride (Zacks)
08:52AM	Pharma, Opendoor, Tesla: Trending Stocks (Yahoo Finance Video)
Sep-02-25 09:05PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +34.84%
06:00PM	More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off. (Barrons.com)
04:06PM	Ionis Pharma Hits Four-Year High On A 'Home Run' In Triglycerides Treatment (Investor's Business Daily)
04:00PM	Ionis to present at upcoming investor conferences (Business Wire)
10:38AM	Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction (Benzinga)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:01AM	Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch. (Investor's Business Daily)
07:00AM	Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG) (Business Wire)
01:34AM	Ionis Pharmaceuticals (IONS) Gains FDA Approval for HAE Drug, Piper Sandler Lifts Target (Insider Monkey)
Aug-28-25 11:49PM	J.P. Morgan Raises the PT on Ionis Pharmaceuticals (IONS), Keeps a Hold Rating (Insider Monkey)
Aug-21-25 05:49PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
02:24PM	Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder (Benzinga)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LOSCALZO JOSEPH	Director	Mar 03 '26	Option Exercise	38.06	832	31,666	37,162	Mar 05 06:14 PM
LOSCALZO JOSEPH	Director	Mar 04 '26	Option Exercise	38.06	200	7,612	36,530	Mar 05 06:14 PM
LOSCALZO JOSEPH	Director	Mar 03 '26	Sale	80.33	832	66,833	36,330	Mar 05 06:14 PM
LOSCALZO JOSEPH	Director	Mar 04 '26	Sale	80.00	200	16,000	36,330	Mar 05 06:14 PM
KLEIN JOSEPH III	Director	Mar 03 '26	Option Exercise	40.76	16,000	652,120	32,346	Mar 05 06:14 PM
KLEIN JOSEPH III	Director	Mar 03 '26	Sale	79.51	21,332	1,696,181	11,014	Mar 05 06:14 PM
Diaz Allene M.	Director	Mar 03 '26	Option Exercise	39.72	40,321	1,601,607	58,689	Mar 05 06:14 PM
Diaz Allene M.	Director	Mar 03 '26	Sale	79.35	54,878	4,354,428	3,811	Mar 05 06:14 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Mar 03 '26	Option Exercise	35.97	20,106	723,254	42,647	Mar 05 06:14 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Mar 03 '26	Sale	79.40	20,106	1,596,433	22,541	Mar 05 06:14 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Mar 03 '26	Option Exercise	53.73	65,089	3,497,531	165,643	Mar 05 06:13 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Mar 03 '26	Sale	79.23	85,089	6,741,669	80,554	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 03 '26	Option Exercise	44.27	1,699	75,215	6,471	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 04 '26	Option Exercise	45.71	439	20,066	4,585	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 03 '26	Sale	79.36	4,096	325,059	41,317	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 03 '26	Sale	80.42	2,124	170,808	4,347	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 04 '26	Sale	80.00	439	35,120	4,347	Mar 05 06:13 PM
LOSCALZO JOSEPH	Director	Mar 03 '26	Proposed Sale	80.00	24,000	1,920,000		Mar 03 05:51 PM
Baroldi Mariana	Officer	Mar 03 '26	Proposed Sale	80.00	8,198	655,840		Mar 03 05:43 PM
Baroldi Joseph	Officer	Mar 03 '26	Proposed Sale	79.36	4,096	325,059		Mar 03 05:42 PM
KLEIN JOSEPH III	Director	Mar 03 '26	Proposed Sale	77.07	65,345	5,035,928		Mar 03 05:35 PM
Devers Shannon L.	Officer	Mar 03 '26	Proposed Sale	79.50	39,014	3,101,613		Mar 03 05:34 PM
Swayze Eric	EVP Research	Feb 13 '26	Sale	81.76	15,642	1,278,914	32,105	Feb 13 07:40 PM
PARSHALL B LYNNE	Director	Feb 11 '26	Sale	82.72	5,000	413,588	56,344	Feb 13 07:40 PM
Swayze Eric	Officer	Feb 13 '26	Proposed Sale	81.65	15,642	1,277,169		Feb 13 04:04 PM
PARSHALL B LYNNE	Director	Feb 11 '26	Proposed Sale	82.74	10,000	827,400		Feb 11 04:02 PM
Monia Brett P	Chief Executive Officer	Feb 06 '26	Sale	85.79	29,430	2,524,820	254,497	Feb 10 05:04 PM
Monia Brett P	Officer	Feb 06 '26	Proposed Sale	85.55	290,203	24,826,867		Feb 06 04:09 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Feb 02 '26	Option Exercise	53.73	65,089	3,497,531	128,919	Feb 04 04:06 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Feb 02 '26	Sale	82.93	85,089	7,056,216	80,293	Feb 04 04:06 PM
Swayze Eric	EVP Research	Jan 30 '26	Sale	82.93	6,179	512,446	47,747	Feb 02 08:52 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 30 '26	Sale	83.45	6,179	515,630	69,702	Feb 02 08:52 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 30 '26	Sale	83.53	6,179	516,153	71,983	Feb 02 08:51 PM
Monia Brett P	Chief Executive Officer	Jan 30 '26	Sale	82.72	62,970	5,208,979	283,927	Feb 02 08:51 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 30 '26	Sale	83.24	6,988	581,702	132,881	Feb 02 08:51 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 30 '26	Sale	83.03	6,179	513,048	66,247	Feb 02 08:51 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 30 '26	Sale	82.95	5,885	488,141	100,293	Feb 02 08:51 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 30 '26	Sale	82.96	5,296	439,364	45,413	Feb 02 08:51 PM
BENNETT C FRANK	Officer	Feb 02 '26	Proposed Sale	82.93	85,089	7,056,227		Feb 02 04:22 PM
Baroldi Joseph	Officer	Jan 30 '26	Proposed Sale	83.02	5,296	439,694		Jan 30 08:50 PM
Birchler Brian	Officer	Jan 30 '26	Proposed Sale	82.91	6,179	512,272		Jan 30 08:47 PM
BENNETT C FRANK	Officer	Jan 30 '26	Proposed Sale	82.91	5,885	487,898		Jan 30 08:40 PM
HOUGEN ELIZABETH L	Officer	Jan 30 '26	Proposed Sale	83.01	6,988	580,049		Jan 30 08:34 PM
Monia Brett P	Officer	Jan 30 '26	Proposed Sale	82.96	62,970	5,223,749		Jan 30 08:23 PM
O'NEIL PATRICK R.	Officer	Jan 30 '26	Proposed Sale	83.01	6,179	512,906		Jan 30 08:20 PM
Swayze Eric	Officer	Jan 30 '26	Proposed Sale	83.01	6,179	512,906		Jan 30 08:19 PM
Schneider Eugene	Officer	Jan 30 '26	Proposed Sale	83.01	6,179	512,906		Jan 30 08:14 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 22 '26	Sale	81.34	3,977	323,490	22,541	Jan 23 05:51 PM
Devers Shannon L.	Officer	Jan 22 '26	Proposed Sale	81.34	3,977	323,490		Jan 22 04:07 PM
Baroldi Mariana	Member of immediate family of	Jan 16 '26	Proposed Sale	80.00	1,171	93,680		Jan 21 11:51 AM
YANG MICHAEL J.	Director	Jan 15 '26	Option Exercise	0.00	1,930	0	7,940	Jan 20 08:21 PM
Swayze Eric	EVP Research	Jan 15 '26	Option Exercise	0.00	21,366	0	51,819	Jan 20 08:21 PM
Swayze Eric	EVP Research	Jan 15 '26	Option Exercise	0.00	111	0	367	Jan 20 08:21 PM
Swayze Eric	EVP Research	Jan 16 '26	Sale	75.34	9,884	744,661	41,935	Jan 20 08:21 PM
Swayze Eric	EVP Research	Jan 16 '26	Sale	75.97	49	3,723	318	Jan 20 08:21 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 15 '26	Option Exercise	0.00	21,685	0	73,192	Jan 20 08:21 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 16 '26	Sale	75.59	9,302	703,138	63,890	Jan 20 08:21 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 15 '26	Option Exercise	0.00	21,473	0	75,362	Jan 20 08:20 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 16 '26	Sale	75.84	9,191	697,045	66,171	Jan 20 08:20 PM
Monia Brett P	Chief Executive Officer	Jan 15 '26	Option Exercise	0.00	89,145	0	268,717	Jan 20 08:20 PM
Monia Brett P	Chief Executive Officer	Jan 16 '26	Sale	74.82	44,034	3,294,624	224,683	Jan 20 08:20 PM
Kordasiewicz Holly B.	EVP, Chief Development Officer	Jan 15 '26	Option Exercise	0.00	11,119	0	18,859	Jan 20 08:18 PM
Kordasiewicz Holly B.	EVP, Chief Development Officer	Jan 16 '26	Sale	75.66	4,141	313,308	14,718	Jan 20 08:18 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Jan 15 '26	Option Exercise	0.00	7,013	0	18,212	Jan 20 08:18 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Jan 16 '26	Sale	75.96	1,823	138,475	16,389	Jan 20 08:18 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 15 '26	Option Exercise	0.00	28,729	0	139,229	Jan 20 08:18 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 16 '26	Sale	75.22	12,922	971,993	126,307	Jan 20 08:18 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 15 '26	Option Exercise	0.00	17,377	0	34,871	Jan 20 08:18 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 16 '26	Sale	75.95	8,353	634,410	26,518	Jan 20 08:18 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 15 '26	Option Exercise	0.00	20,089	0	68,915	Jan 20 08:18 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 16 '26	Sale	75.11	8,480	636,933	60,435	Jan 20 08:18 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 15 '26	Option Exercise	0.00	21,055	0	103,734	Jan 20 08:18 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 16 '26	Sale	75.15	8,977	674,622	94,757	Jan 20 08:18 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '26	Option Exercise	0.00	17,037	0	47,338	Jan 20 08:18 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '26	Option Exercise	0.00	2,850	0	5,921	Jan 20 08:18 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '26	Sale	75.75	6,907	523,205	40,431	Jan 20 08:18 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '26	Sale	75.78	1,149	87,071	4,772	Jan 20 08:18 PM
Swayze Eric	Officer	Jan 16 '26	Proposed Sale	76.23	9,884	753,501		Jan 16 07:31 PM
Baroldi Joseph	Officer	Jan 16 '26	Proposed Sale	80.00	6,999	559,920		Jan 16 06:55 PM
BENNETT C FRANK	Officer	Jan 16 '26	Proposed Sale	76.22	8,977	684,264		Jan 16 06:50 PM
Birchler Brian	Officer	Jan 16 '26	Proposed Sale	76.22	8,480	646,376		Jan 16 06:47 PM
HOUGEN ELIZABETH L	Officer	Jan 16 '26	Proposed Sale	76.24	12,922	985,109		Jan 16 06:46 PM
Monia Brett P	Officer	Jan 16 '26	Proposed Sale	76.24	44,034	3,357,167		Jan 16 06:44 PM
O'NEIL PATRICK R.	Officer	Jan 16 '26	Proposed Sale	76.23	9,191	700,603		Jan 16 06:42 PM
Schneider Eugene	Officer	Jan 16 '26	Proposed Sale	76.23	9,302	709,072		Jan 16 06:40 PM
Devers Shannon L.	Officer	Jan 16 '26	Proposed Sale	76.22	8,353	636,626		Jan 16 06:36 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 07 '26	Option Exercise	51.25	44,199	2,265,415	43,039	Jan 09 05:08 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 07 '26	Sale	85.08	44,199	3,760,577	17,494	Jan 09 05:08 PM
Devers Shannon L.	Officer	Jan 07 '26	Proposed Sale	84.68	9,390	795,117		Jan 07 04:06 PM
Swayze Eric	EVP Research	Jan 02 '26	Option Exercise	60.89	23,463	1,428,662	48,791	Jan 06 05:35 PM
Swayze Eric	EVP Research	Jan 02 '26	Sale	79.12	23,463	1,856,325	30,453	Jan 06 05:35 PM
Swayze Eric	Officer	Jan 02 '26	Proposed Sale	69.02	23,463	1,619,416		Jan 02 04:49 PM
WENDER JOSEPH H	Director	Dec 01 '25	Sale	80.82	28,000	2,262,848	36,035	Dec 03 07:01 PM
Joseph Wender	Director	Dec 01 '25	Proposed Sale	81.99	14,479	1,187,133		Dec 01 06:14 PM
KLEIN JOSEPH III	Director	Nov 25 '25	Option Exercise	0.00	12,000	0	4,000	Nov 28 05:51 PM
KLEIN JOSEPH III	Director	Nov 25 '25	Sale	80.00	12,000	960,000	0	Nov 28 05:51 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Nov 25 '25	Option Exercise	53.77	16,777	902,099	34,271	Nov 28 05:51 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Nov 25 '25	Sale	80.91	16,777	1,357,442	17,494	Nov 28 05:51 PM
Devers Shannon L.	Officer	Nov 25 '25	Proposed Sale	80.91	42,322	3,424,273		Nov 25 05:53 PM
KLEIN JOSEPH III	Director	Nov 25 '25	Proposed Sale	80.00	12,000	960,000		Nov 25 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IONS

Ionis Pharmaceuticals Inc

Upgrade your FINVIZ experience